CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial

VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI
Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”)
today announced that during the month of August it has enrolled 28
patients in its ongoing Phase 3 trial of its investigational
immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients
with advanced primary head and neck cancer. Total patient enrollment for
the trial is now 905 as of August 31, 2016.
The Multikine Phase 3 study is enrolling patients with advanced primary
(not yet treated) squamous cell carcinoma of the head and neck. The
objective of the study is to demonstrate a statistically significant
improvement in the overall survival of enrolled patients who are treated
with the Multikine treatment regimen plus standard of care (“SOC”) vs.
subjects who are treated with SOC only.
About Multikine
Multikine is an investigational immunotherapeutic agent that is being
tested in an open-label, randomized, controlled, global pivotal Phase 3
clinical trial as a potential first-line (before any other, right after
diagnosis) treatment for advanced primary squamous cell carcinoma of the
head and neck. Multikine is designed to be a different type of therapy
in the fight against cancer: one that appears to have the potential to
work with the body’s natural immune system in the fight against tumors.
Multikine is also being tested in a Phase 1 study at University of
California, San Francisco (UCSF), as a potential treatment for peri-anal
warts in HIV/HPV co-infected men and women. Dr. Joel Palefsky, a
world-renowned scientist and Key Opinion Leader (KOL) in human papilloma
virus (HPV) research and the prevention of anal cancer, is the Principal
Investigator at UCSF.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate the immune
system to fight cancer and infectious diseases. Its lead investigational
immunotherapy, Multikine (Leukocyte Interleukin, Injection), is
currently being studied in a pivotal Phase 3 clinical trial as a
potential neoadjuvant treatment for patients with squamous cell
carcinoma of the head and neck. If the study endpoint, which is an
improvement in overall survival of the subjects treated with the
Multikine treatment regimen plus the current standard of care (SOC) as
compared to subjects treated with the current SOC only, is satisfied,
the study results will be used to support applications that the Company
plans to submit to regulatory agencies in order to seek commercial
marketing approvals for Multikine in major markets around the world.
Additional clinical indications for Multikine that are being
investigated include the treatment of cervical dysplasia in HIV/HPV
co-infected women, and the treatment of peri-anal warts in HIV/HPV
co-infected men and women. A Phase 1 trial of the former indication has
been completed at the University of Maryland. The latter indication is
now in a Phase 1 trial at UCSF. CEL-SCI has issued patents on Multikine
from the US, Europe, China and Japan.
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope
Antigen Presentation System) technology for the potential treatment of
pandemic influenza in hospitalized patients and as a potential vaccine
for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. When
used in this press release, the words “intends,” “believes,”
“anticipated,” “plans” and “expects,” and similar expressions, are
intended to identify forward-looking statements. Such statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate the
clinical results demonstrated in clinical studies, timely development of
any potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in manufacturing
any of the Company’s potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in
CEL-SCI Corporation’s filings with the Securities and Exchange
Commission, including but not limited to its report on Form 10-K for the
year ended September 30, 2015. The Company undertakes no obligation to
publicly release the result of any revision to these forward-looking
statements which may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events.

*Multikine (Leukocyte Interleukin, Injection) is the trademark that
CEL-SCI has registered for this investigational therapy, and this
proprietary name is subject to FDA review in connection with the
Company’s future anticipated regulatory submission for approval.
Multikine has not been licensed or approved for sale, barter or exchange
by the FDA or any other regulatory agency. Similarly, its safety or
efficacy have not been established for any use. Moreover, no definitive
conclusions can be drawn from the early-phase, clinical-trials data
involving the investigational therapy Multikine. Further research is
required, and early-phase clinical trial results must be confirmed in
the Phase 3 clinical trial of this investigational therapy that is
currently in progress.